Tools

LEADER 02340cam 2200505 i 4500

001 on1329983407;

003 OCoLC;

005 20220705164247.0;

006 m o d f ;

007 cr b||||||||||;

008 220614s2022 dcua ob f000 0 eng c;

042 a| pcc;

043 a| n-us---;

049 a| ERE#;

074 a| 1016-C (online);

086 0 a| Y 4.OV 2:C 81/4;

245 14 a| The coronavirus vaccine manufacturing failures of Emergent BioSolutions /c| Select Subcommittee on the Coronavirus Crisis, Committee on Oversight and Reform.;

264 1 a| [Washington, D.C.] :b| Select Subcommittee on the Coronavirus Crisis, Committee on Oversight and Reform,c| 2022.;

300 a| 1 online resource (26 pages) :b| color illustrations;

336 a| textb| txt2| rdacontent;

337 a| computerb| c2| rdamedia;

338 a| online resourceb| cr2| rdacarrier;

588 a| Description based on online resource; title from PDF title page (Coronavirus.house.gov, viewed June 14, 2022).;

500 a| "Staff report, May 2022.";

500 a| Redacted.;

500 a| GPO Cataloging Record Distribution Program (CRDP).;

504 a| Includes bibliographical references (pages 17-26).;

610 20 a| Emergent BioSolutions.=| ^A1435617;

650 0 a| Vaccinesx| Standardsz| United States.=| ^A140104;

650 0 a| Vaccines industryx| Government policyz| United States.=| ^A577688;

650 0 a| Vaccines industryx| Subsidiesz| United States.=| ^A577688;

650 0 a| COVID-19 (Disease)x| Vaccinationz| United States.=| ^A1407776;

650 0 a| COVID-19 (Disease)x| Treatmentz| United States.=| ^A1407776;

650 0 a| COVID-19 (Disease)z| United Statesx| Prevention.=| ^A1407776;

650 0 a| Coronavirus infectionsz| United Statesx| Prevention.=| ^A828712;

856 40 u| https://purl.fdlp.gov/GPO/gpo1834467| 0;

922 a| UNREPORTEDPUBSSTAFF;

922 a| BIBCONEWb| 20220614;

949 a| Click on web addressw| asish| joyner94;

596 a| 1;

998 a| 5832721;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 5832721-1001l| JNETm| JOYNERr| Ys| Yt| JNE1DOu| 7/11/2022x| EDOCUMENTz| JERESOURCE;

The coronavirus vaccine manufacturing failures of Emergent BioSolutions / Select Subcommittee on the Coronavirus Crisis, Committee on Oversight and Reform.

Author/creator	United States
Format	Electronic
Publication	[Washington, D.C.] : Select Subcommittee on the Coronavirus Crisis, Committee on Oversight and Reform, 2022.
Description	1 online resource (26 pages) : color illustrations
Supplemental Content	https://purl.fdlp.gov/GPO/gpo183446
Subjects	Emergent BioSolutions. Vaccines--Development. --Standards. --United States. Vaccines--Standards. --United States. Vaccines industry--Government policy. --United States. Vaccines industry--Subsidies. --United States. COVID-19 (Disease)--Vaccination. --United States. COVID-19 (Disease)--Treatment. --United States. COVID-19 (Disease)--United States. --Prevention. Coronavirus infections--United States. --Prevention.

General note	"Staff report, May 2022."
General note	Redacted.
General note	GPO Cataloging Record Distribution Program (CRDP).
Bibliography note	Includes bibliographical references (pages 17-26).
Source of description	Description based on online resource; title from PDF title page (Coronavirus.house.gov, viewed June 14, 2022).
GPO item number	1016-C (online)
Govt. docs number	Y 4.OV 2:C 81/4

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

The coronavirus vaccine manufacturing failures of Emergent BioSolutions / Select Subcommittee on the Coronavirus Crisis, Committee on Oversight and Reform.

Click here for more information about this title

Availability